MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial) (NCT05564390)
Master Screening and Reassessment Protocol (MSRP) for the NCI MyeloMATCH Clinical Trials
🩺 Plain-English Summary (8th-Grade Level)
This MyeloMATCH Master Screening and Reassessment Protocol (MSRP) evaluates the use of a screening tool and specific laboratory tests to help improve participants' ability to register to clinical trials throughout the course of their myeloid cancer (acute myeloid leukemia or myelodysplastic syndrome) treatment. This study involves testing patients' bone marrow and blood for certain biomarkers. A biomarker (sometimes called a marker) is any molecule in the body that can be measured. Doctors look at markers to learn what is happening in the body. Knowing about certain markers can give doctors more information about what is driving the cancer and how to treat it. Testing patients' bone marrow and blood will show doctors if patients have markers that specific drugs can target. The marker testing in this study will let doctors know if they can match patients with a treatment study (myeloMATCH clinical trial) that tests treatment for the type of cancer they have or continue standard of care treatment with their doctor on the Tier Advancement Pathway (TAP).
Who can join: Review the eligibility criteria below.
Location: University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
Age range: 18 Years
🧪 Interventions in This Study
- Azacitidine (DRUG)
- Busulfan (DRUG)
- Cytarabine (DRUG)
- Daunorubicin Hydrochloride (DRUG)
- Decitabine and Cedazuridine (DRUG)
- Emavusertib (BIOLOGICAL)
- Enasidenib (DRUG)
- Epoetin Alfa (BIOLOGICAL)
- Fludarabine (DRUG)
- Gemtuzumab Ozogamicin (DRUG)
- Gilteritinib (DRUG)
- Liposome-encapsulated Daunorubicin-Cytarabine (DRUG)
- Luspatercept (BIOLOGICAL)
- Melphalan (DRUG)
- Olutasidenib (DRUG)
- Placebo Administration (DRUG)
- Venetoclax (DRUG)
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (348 Sites)
Showing the first 25 of 348 sites.
- University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
- Mayo Clinic Hospital in Arizona — Phoenix, Arizona
- Banner University Medical Center - Tucson — Tucson, Arizona
- University of Arizona Cancer Center-North Campus — Tucson, Arizona
- University of Arkansas for Medical Sciences — Little Rock, Arkansas
- Alta Bates Summit Medical Center-Herrick Campus — Berkeley, California
- Kaiser Permanente Dublin — Dublin, California
- Kaiser Permanente-Fremont — Fremont, California
- Kaiser Permanente Fresno Orchard Plaza — Fresno, California
- Kaiser Permanente-Fresno — Fresno, California
- UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care — Irvine, California
- Tibor Rubin VA Medical Center — Long Beach, California
- Cedars-Sinai Medical Center — Los Angeles, California
- Kaiser Permanente- Modesto MOB II — Modesto, California
- Kaiser Permanente-Modesto — Modesto, California
- Kaiser Permanente-Oakland — Oakland, California
- UC Irvine Health/Chao Family Comprehensive Cancer Center — Orange, California
- Kaiser Permanente-Roseville — Roseville, California
- Kaiser Permanente Downtown Commons — Sacramento, California
- University of California Davis Comprehensive Cancer Center — Sacramento, California
- Kaiser Permanente-South Sacramento — Sacramento, California
- Kaiser Permanente-San Francisco — San Francisco, California
- UCSF Medical Center-Parnassus — San Francisco, California
- Kaiser Permanente-Santa Teresa-San Jose — San Jose, California
- Kaiser Permanente San Leandro — San Leandro, California
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Acute Myeloid Leukemia
- PRGN-3006 Adoptive Cellular Therapy for CD33-Positive Relapsed or Refractory AML, MRD Positive AML or Higher Risk MDS — Tampa, Florida
- Gamma Delta T-cell Infusion for AML at High Risk of Relapse After Allo HCT — Tampa, Florida
- Daunorubicin and Cytarabine With or Without Uproleselan in Treating Older Adult Patients With Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy — Little Rock, Arkansas
- Azacitidine and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia — Burbank, California
- A Study to Assess Safety, Tolerability and Preliminary Efficacy of Bexmarilimab in Combination With Standard of Care in Patients With Hematological Malignancies — Duarte, California
- A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia — Madera, California
Explore by condition: All Acute Myeloid Leukemia clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.